LU 302872

Drug Profile

LU 302872

Alternative Names: BSF-302872; LU-302872

Latest Information Update: 12 Feb 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Class Propionic acids; Pyrimidines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists; Endothelin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 31 Dec 2012 Discontinued - Preclinical for Benign prostatic hyperplasia in Germany (PO) before 2012
  • 09 Dec 2003 No development reported - Preclinical for Benign prostatic hyperplasia in Germany (PO)
  • 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top